This article is more than 5 years old. Information may no longer be current.

Intra-articular Wnt pathway inhibitor yielded significant improvements in knee OA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LIVERPOOL, England — Patients with knee osteoarthritis treated with a novel, intra-articular Wnt pathway inhibitor had significant improvements in symptomatic and medial joint space width compared to patients treated with placebo, according to results presented at the OARSI 2018 World Congress on Osteoarthritis.

Yusuf Yazici, MD, and colleagues randomly assigned 455 patients with knee OA with Kellgren-Lawrence grade 2 and grade 3 to receive a 0.03-mg, 0.07-mg or 0.23-mg injection of a novel, intra-articular Wnt pathway inhibitor (SM04690) or placebo. Patients were categorized into two subgroups: those with unilateral symptomatic knee OA and those with unilateral symptomatic knee OA without widespread pain.

“We looked at WOMAC pain and function as the primary [patient-reported outcome] PRO outcomes, signs and symptoms and looked at radiographs at 6 months, 12 months with the [Osteoarthritis Initiative] OAI protocol of semi-flexed with the positioners, which has the high reproducible results which the OAI initiative has also shown,” Yazici told Healio Rheumatology.

Compared to baseline, results showed clinically meaningful improvements in WOMAC pain and function at all time points in all groups treated with SM04690. Researchers found patients in the pre-specified unilateral symptomatic subgroup had significant improvements in WOMAC pain and clinically meaningful and significant improvements in WOMAC function when receiving the 0.07-mg dose of SM04690 vs. the placebo group.

At week 39 and week 52, patients in the post-hoc unilateral symptomatic group without widespread pain receiving the 0.07-mg dose of SM04690 had clinically meaningful and significant improvements in WOMAC pain and function compared with placebo. Researchers found a significant increase in medial joint space width from baseline in patients with unilateral symptomatic OA and unilateral symptomatic without widespread pain OA receiving 0.07 mg of SM04690. – by Casey Tingle and Rob Volansky

Reference:

Yazici Y, et al. Poster 550. Presented at: OARSI 2018 World Congress on Osteoarthritis; April 26-29, 2018; Liverpool, England.

Disclosure: Healio Rheumatology was unable to confirm Yazici’s relevant financial disclosures at the time of publication.